Skip to main content

Cannabis Compound Reduces Agitation In Alzheimer’s Patients

Attendees of the Alzheimer’s Association International Conference in July 201...

Credit: Courtesy of Alzheimer's Association

Above: Attendees of the Alzheimer’s Association International Conference in July 2017 are pictured in this photo.

Cannabis Compound Reduces Agitation In Alzheimer's Patients

GUEST:

Heather Snyder, Ph.D., senior director of medical and scientific relations, Alzheimer’s Association

A recent study found that patients with Alzheimer's disease who took a synthetic cannabis compound experienced less agitation, one of the most common symptoms of the disease.

That research is just one of the takeaways from this year’s Alzheimer’s Association International Conference. The goal of the conference is to advance dementia science in an effort to learn methods of prevention, treatment and improved diagnosis.

A roundup of the new research will be presented at an event at the University of San Diego Wednesday at 6 p.m. The event is open to the public, but attendees are encouraged to make a reservation by calling 800-272-3900.

Heather Snyder, who heads medical and scientific relations for the Alzheimer's Association, joins Midday Edition on Wednesday with an overview of the latest research on Alzheimer's disease.

Want more KPBS news?
Find us on Twitter and Facebook, or subscribe to our newsletters.

To view PDF documents, Download Acrobat Reader.